Shield Therapeutics plc (LON:STX) Insider Anders Lundstrom Buys 575,000 Shares

Shield Therapeutics plc (LON:STX) insider Anders Lundstrom acquired 575,000 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of GBX 4 ($0.05) per share, with a total value of £23,000 ($28,949.02).

Shield Therapeutics Stock Performance

LON STX opened at GBX 4.14 ($0.05) on Friday. Shield Therapeutics plc has a fifty-two week low of GBX 1.06 ($0.01) and a fifty-two week high of GBX 5.95 ($0.07). The stock has a market cap of £40.83 million, a price-to-earnings ratio of -1.07 and a beta of 1.42. The business has a fifty day moving average of GBX 2.81 and a 200-day moving average of GBX 3.40. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.